And how about for the elderly population? What are the recommendations for advanced stage disease?

Well, the problem with the elderly is that they do not tolerate escalated BCOP.

So the best studied and the first option we suggest is giving a combination of six cycles of the PD-1 inhibitor nivolumab with AVD.

This results in a substantial improvement in the outcome of these patients in what was previously the standard, whether it was ABVD or AVD plus BVD.

Now, we also say that if you have a very fit and not so very elderly patient, you could try BRICAD in those patients also because they, Dennis said, they have less toxicity with BRICAD than with escalated BCUP.

And

of course, brentuximab, vedotin, as I said, it's targeted chemotherapy.

It's not a chemo-free approach.